ADC Therapeutics SA (ADCT) Tops Q3 EPS by 10c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $18.46 million versus the consensus estimate of $18.46 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Bonk, Inc. posts $5.5M revenue in H1 2026, reports $7.88M net loss
• Onemeta reports 500% usage rise and $2.4M cash flow in H1 2026